# Thymosin Alpha-1 (Tα1) — Full Research Profile

## Quick Reference

| Property | Detail |
|---|---|
| **Other Names** | Thymalfasin, Zadaxin™, Tα1, TA1 |
| **Type** | Endogenous thymic peptide / Immunomodulator |
| **Structure** | 28 amino acid acetylated polypeptide |
| **Molecular Weight** | 3,108 Da |
| **Sequence** | Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn-OH |
| **Endogenous Source** | Thymus gland (proteolytic cleavage of prothymosin-alpha / PTMA) |
| **Route** | Subcutaneous injection |
| **Half-life** | < 3 hours (peak serum at 1–2 h post-SC injection) |
| **Regulatory Status** | Approved in 35+ countries (Asia, South America, Europe); FDA orphan drug designations for melanoma, Hep B, DiGeorge syndrome, HCC |
| **Commercial Form** | Zadaxin™ (SciClone Pharmaceuticals) — 1.6 mg lyophilized vials |

---

## 1. Background & Discovery

Thymosin Alpha-1 was first isolated in 1977 from "thymosin fraction 5," a partially purified extract of bovine thymus tissue, by Allan Goldstein and colleagues at George Washington University. The thymus had been recognized since the 1960s as critical for immune development — neonatal thymectomy caused severe immunodeficiency, wasting disease, and lymphocyte depletion in animal models. Thymosin fraction 5 contains ~40 polypeptides; Tα1 was the first individual peptide isolated and characterized from this mixture.

Tα1 is endogenously produced in humans by proteolytic cleavage of prothymosin-alpha (PTMA), a larger 113-amino acid nuclear protein. Serum levels of Tα1 decline with age and thymic involution, correlating with immunosenescence — the age-related decline in immune function.

**Key discovery references:**
- Goldstein AL, et al. (1977). Thymosin α1: isolation and sequence analysis of an immunologically active thymic polypeptide. *PNAS* 74(2):725–729.
- Low TLK, et al. (1979). Isolation, characterization, and biological activities of thymosin α1. *J Biol Chem* 254:981–986.

---

## 2. Mechanism of Action

Tα1 has a **pleiotropic mechanism** affecting multiple arms of the immune system:

### 2.1 Toll-Like Receptor (TLR) Agonism
- Acts as an agonist of **TLR-2** and **TLR-9** on myeloid and plasmacytoid dendritic cells (DCs)
- TLR-9 activation triggers the **MyD88/IRF7 signaling pathway**, inducing type I interferon production
- TLR-2 stimulation promotes DC maturation and enhanced antigen presentation
- This bridges innate and adaptive immunity — a critical mechanism for anti-viral and anti-tumor responses

### 2.2 T-Cell Maturation & Activation
- Promotes differentiation and maturation of immature T-cell progenitors into functional **CD4+** and **CD8+** T cells
- Upregulates **IL-2 receptor expression** on T cells, enhancing responsiveness to IL-2 signaling
- Increases T-cell rosette formation in patients with T-cell lymphopenia
- Restores mHLA-DR (monocyte human leukocyte antigen-DR) expression — a key marker of immune competence in sepsis

### 2.3 Natural Killer (NK) Cell Activation
- Directly activates NK cells, enhancing cytolytic capacity against virus-infected and tumor cells
- Promotes maturation of NK cell progenitors (especially in combination with interferons)

### 2.4 Dendritic Cell Modulation
- Promotes DC maturation via TLR signaling
- Enhances cross-presentation of antigens to CD8+ T cells
- Increases expression of MHC class I molecules on target cells

### 2.5 Cytokine Modulation
- **Upregulates:** IL-2, IL-10, IL-12, IFN-α, IFN-γ
- **Downregulates:** IL-1β, TNF-α (reduces excessive inflammatory response)
- This dual action makes Tα1 an immunomodulator rather than a simple immunostimulant — it can both enhance deficient immunity AND dampen harmful hyperinflammation

### 2.6 Anti-Viral Mechanisms
- Increases MHC class I/viral antigen display on infected cells
- Decreases viral replication directly
- Enhances T-cell-dependent antibody production (relevant for vaccine adjuvant use)

### 2.7 Anti-Tumor Mechanisms
- Direct anti-proliferative effects on tumor cells (especially small tumor burden)
- Immune priming for chemo/immunotherapy effectiveness
- Long-term immune maintenance for sustained anti-tumor surveillance
- Enhanced NK cell and cytotoxic T-cell activity against tumor targets

### 2.8 Antioxidant Properties
- Protective against oxidative damage via upregulation of liver superoxide dismutase (SOD) and glutathione peroxidase (GPx)

**Key MOA references:**
- Romani L, et al. (2007). Thymosin α1 activates TLR9/MyD88/IRF7 signaling. *Int Immunol* 19(11):1261–1270.
- Tuthill C, et al. (2010). Thymosin α1: past clinical experience and future promise. *Ann NY Acad Sci* 1194:179–189.
- Garaci E, et al. (2012). Thymosin α1 and cancer: action on immune effector and tumor target cells. *Ann NY Acad Sci* 1269:26–33.

---

## 3. Pharmacokinetics

| Parameter | Value |
|---|---|
| **Route** | Subcutaneous (SC) injection |
| **Tmax** | 1–2 hours post-injection |
| **Cmax** | 30–80 ng/mL (after standard 1.6 mg dose) |
| **Elimination half-life** | < 3 hours |
| **Accumulation** | No apparent accumulation with repeated dosing |
| **Bioavailability** | High via SC route |
| **Metabolism** | Presumed proteolytic degradation |

The short half-life supports twice-weekly dosing for sustained immune modulation. Despite rapid clearance, immunological effects persist well beyond the serum half-life due to downstream cellular activation cascades.

**Reference:** Rost KL, et al. (1999). Pharmacokinetics of thymosin alpha1 after subcutaneous injection of three different formulations in healthy volunteers. *Int J Clin Pharmacol Ther* 37(1):51–57. PMID: 10027483.

---

## 4. Dosing Protocols

### 4.1 Standard Clinical Dose (Zadaxin Label)
- **1.6 mg SC twice weekly** for 6–12 months (hepatitis B/C)
- Reconstitute lyophilized powder with 1 mL sterile water → 1.6 mg/mL solution

### 4.2 Sepsis Protocol (ETASS Trial)
- **1.6 mg SC twice daily × 5 days**, then **once daily × 2 days** (7-day total course)
- Start within 4 hours of enrollment

### 4.3 TESTS Phase 3 Sepsis Trial (BMJ 2025)
- **1.6 mg SC every 12 hours × 7 days**

### 4.4 Cancer Adjuvant
- **1.6 mg SC twice weekly × 6 months**, or administered between chemotherapy cycles for treatment duration

### 4.5 Peptide Clinic Protocols (Off-Label/Research)
- **Initiation:** 300 mcg SC daily × 1 week (assess tolerance)
- **Maintenance:** 500 mcg SC daily for 8 weeks
- **Alternative:** 1.6 mg SC twice weekly (mirrors clinical data)

### 4.6 Dose Range Studied
- Single doses: 0.8–6.4 mg
- Multiple dose regimens: 1.6–16 mg/day for 5–7 days
- Up to 9.6 mg/m² tolerated in cancer trials without serious adverse effects

---

## 5. Clinical Evidence by Indication

### 5.1 Hepatitis B (Chronic)

**Level of Evidence: Strong (RCTs, pooled analyses, approved indication)**

- Pooled analysis of 3 RCTs (223 patients): 36% virological response (HBV DNA + HBeAg negative at 12-month follow-up) vs 19% placebo/no treatment
- Notable delayed therapeutic response — benefits continue to accrue 12+ months after treatment completion
- Combination with IFN-α shows enhanced efficacy (ALT normalization 37.1% vs 16.2% IFN alone vs 2.7% placebo in one US Phase 3 trial)
- Now largely superseded by direct-acting antivirals but historically significant

**References:**
- Chan HL, et al. (2001). Randomized controlled trial of thymosin α1 vs placebo in chronic hepatitis B. *Hepatology* 33(3):1536–1542.
- Chien RN, et al. (1998). Efficacy of thymosin α1 in patients with chronic hepatitis B. *Hepatology* 27:1383–1387.
- Zadaxin prescribing information, SciClone Pharmaceuticals.

### 5.2 Hepatitis C (Chronic)

**Level of Evidence: Moderate (RCTs, combination therapy)**

- Tα1 monotherapy: ineffective for HCV
- Combination with IFN-α: pooled analysis showed sustained ALT response 22.4% vs 9.3% IFN alone (P=0.0096)
- Some studies showed virological response rates of 40–73% with combination therapy
- Now superseded by DAAs (sofosbuvir, etc.)

### 5.3 Sepsis

**Level of Evidence: Mixed (one large negative Phase 3; smaller positive trials; positive meta-analyses)**

#### ETASS Trial (2013) — Positive Signal
- 361 patients, multicenter RCT in China
- 28-day mortality: 26.0% (Tα1) vs 35.0% (control) — P=0.062 (marginal); log-rank P=0.049
- HR 0.74 (95% CI 0.54–1.02)
- Significant improvement in mHLA-DR at days 3 and 7
- **Reference:** Wu J, et al. (2013). *Critical Care* 17:R8. PMID: 23327199. PMC4056079.

#### TESTS Phase 3 Trial (2025) — Negative
- 1,106 patients, double-blinded, placebo-controlled Phase 3
- 28-day mortality: 23.4% (Tα1) vs 24.1% (placebo) — HR 0.99 (95% CI 0.77–1.27; P=0.93)
- No significant benefit on primary or secondary endpoints
- **Reference:** BMJ 2025;388:e082583. PMID: 39814420.

#### Meta-Analyses
- 2025 meta-analysis (Frontiers): OR 0.73 (95% CI 0.59–0.90, P=0.003) for 28-day mortality reduction — but driven largely by smaller, lower-quality Chinese trials
- 2014 meta-analysis: Tα1-based therapy associated with lower mortality, but cautioned about trial quality
- The 2025 TESTS trial significantly weakens the sepsis case

### 5.4 Cancer

**Level of Evidence: Moderate (multiple Phase II trials, some Phase III)**

#### Melanoma
- Phase II: Tα1 + dacarbazine ± IFN-α/IL-2 showed evidence of treatment efficacy in multiple trials
- Mechanisms: direct anti-tumor effect, immune priming for chemo/immunotherapy, long-term immune maintenance
- Pre-clinical: effective in B16 melanoma models, especially with combination immunotherapy

#### Hepatocellular Carcinoma (HCC)
- Tα1 monotherapy: evidence of efficacy (pilot studies)
- Tα1 + TACE (transarterial chemoembolization): survival benefit and improved immunological parameters
- Tα1 + lamivudine, Tα1 + sorafenib: evidence of treatment efficacy
- 2025 retrospective study: Tα1 + lenvatinib + sintilimab improved outcomes in unresectable HCC

#### Non-Small Cell Lung Cancer (NSCLC)
- Tα1 + cisplatin/etoposide/IFN-α2a: evidence of efficacy
- Tα1 + cisplatin/vinorelbine or gemcitabine: evidence of efficacy
- Reduces chemotherapy-induced immunosuppression

#### General Cancer Adjuvant
- Clinical studies in 1,000+ cancer patients demonstrated improved immunological parameters, increased tumor response rates, improved survival and quality of life
- FDA orphan drug designations for melanoma and HCC

**Key references:**
- Garaci E, et al. (2019). A reappraisal of thymosin alpha1 in cancer therapy. *Front Oncol* 9:873. PMC6742685.
- Zadaxin prescribing information (cancer indications section).

### 5.5 COVID-19

**Level of Evidence: Preliminary (retrospective studies, mixed results)**

- One retrospective analysis (76 severe COVID-19 patients): Tα1 treatment associated with mortality of 11.1% vs higher in controls
- Multicenter cohort study (5 hospitals): efficacy remains unclear; potential benefit in elderly/immunocompromised
- Non-severe COVID-19 (1,388 patients, propensity-matched): primary outcomes evaluated
- Used widely in China since April 2020 for COVID-19 treatment
- Rationale: repair overactivation damage, prevent excessive T-cell activation, restore T-cell lymphopenia

**References:**
- Liu Y, et al. (2021). Efficacy evaluation of thymosin alpha 1 in non-severe patients with COVID-19. *Front Med* 8:664776. PMC8102900.
- Yu K, et al. (2021). Efficacy of thymosin alpha 1 in the treatment of COVID-19. *Front Immunol* 12:673693.

### 5.6 Vaccine Adjuvant (Immunosenescence)

**Level of Evidence: Moderate (clinical trials in elderly)**

- Enhances influenza vaccine response in elderly populations
- Improves antibody titers in hemodialysis patients (who have impaired T-cell responses)
- Enhances hepatitis B vaccine response in immunocompromised patients
- Rationale: Tα1 compensates for age-related thymic involution and T-cell dysfunction

**References:**
- Gravenstein S, et al. (2007). Thymosin α1 as an adjunct to influenza vaccination in the elderly. *Vaccine* 25(52):8736-8742. PMID: 17600281.
- Panatto D, et al. (2011). Utility of thymosin α1 (Zadaxin) as co-adjuvant in influenza vaccines: a review. *J Prev Med Hyg* 52(3):111-115.

### 5.7 Other Indications Studied
- **DiGeorge Syndrome:** FDA orphan drug designation; restores T-cell function in thymic aplasia
- **HIV/AIDS:** Tested as immune enhancer; some evidence of CD4+ count improvement
- **Psoriatic Arthritis:** Benefit as immunomodulatory agent
- **Mold Toxicity / Chronic Infections:** Used in integrative medicine settings
- **Acute Pancreatitis:** Meta-analysis (2025) showed Tα1 alleviates inflammation and prevents infection (Frontiers in Immunology)

---

## 6. Safety & Tolerability

### 6.1 Adverse Effects
Tα1 has an **excellent safety profile** across all clinical studies:

- **Most common:** Mild local injection-site reactions (redness, discomfort)
- **Rare:** Muscle atrophy, polyarthralgia, hand swelling/rash
- **No serious drug-related adverse events** reported in the ETASS sepsis trial (361 patients)
- **No serious adverse events** in the TESTS Phase 3 trial (1,106 patients)
- Well tolerated at doses up to 9.6 mg/m² in cancer trials

### 6.2 Contraindications & Precautions
- Use in pregnancy only if clearly needed
- Exercise caution while breastfeeding
- No known drug interactions (but inform physician of all medications)
- Do not reuse syringes/needles

### 6.3 Storage
- Store lyophilized form at -20°C
- Stable for up to 3 weeks at room temperature (lyophilized)
- Long-term: below -18°C in desiccated form
- Reconstituted: store at 4°C for 2–7 days
- For longer storage: add carrier protein (0.1% HSA or BSA)
- Avoid repeated freeze-thaw cycles

---

## 7. Regulatory Status

| Region | Status |
|---|---|
| **35+ countries (Asia, South America, parts of Europe)** | Approved for hepatitis B/C treatment and as immune enhancer |
| **United States (FDA)** | Orphan drug designations: malignant melanoma, chronic active hepatitis B, DiGeorge syndrome, hepatocellular carcinoma. Not FDA-approved as a standard drug. |
| **China** | Widely used; included in COVID-19 treatment protocols (2020) |

The synthetic form (thymalfasin/Zadaxin) is manufactured by SciClone Pharmaceuticals. As of 2024, FDA nomination for bulk drug substance status was submitted (FDA-2024-N-4777).

---

## 8. Key Clinical Trials Summary

| Trial | Year | N | Design | Indication | Key Result |
|---|---|---|---|---|---|
| US Phase 2 (Hep B) | 1990s | 20 | RCT | Chronic HBV | 83% vs 25% response |
| US Phase 3 (Hep B) | 1990s | 99 | RCT | Chronic HBV | 24% vs 12% response |
| Taiwan Phase 3 (Hep B) | 1990s | 104 | RCT | Chronic HBV | 37% vs 25% response |
| Pooled Hep B | 1990s | 223 | Pooled RCTs | Chronic HBV | 36% vs 19% response |
| Italy Phase 2 (Hep C) | — | 15 | Open-label | Chronic HCV | 40% sustained virologic response |
| US Phase 3 (Hep C) | — | 109 | RCT | Chronic HCV | 19.2% vs 9.4% sustained ALT response |
| ETASS (Sepsis) | 2013 | 361 | RCT, single-blind | Severe sepsis | 26.0% vs 35.0% 28-day mortality (P=0.049 log-rank) |
| TESTS (Sepsis) | 2025 | 1,106 | RCT, double-blind Phase 3 | Sepsis | 23.4% vs 24.1% — no difference (P=0.93) |
| Italy HCC pilot | — | 24 | Controlled | HCC + TACE | Survival benefit with Tα1 |
| Melanoma Phase II | — | Various | Phase II | Metastatic melanoma | Evidence of efficacy with combination therapy |
| NSCLC trials | — | 100+ | RCTs | Lung cancer | Improved immunological parameters and survival |

---

## 9. Comparison with Related Peptides

| Feature | Thymosin Alpha-1 (Tα1) | Thymosin Beta-4 (Tβ4) |
|---|---|---|
| Size | 28 amino acids | 43 amino acids |
| MW | 3,108 Da | 4,921 Da |
| Primary function | Immunomodulation | Tissue repair, wound healing, anti-inflammation |
| Mechanism | TLR agonism, T-cell maturation | Actin sequestration, angiogenesis promotion |
| Clinical use | Infections, cancer, immunodeficiency | Corneal repair, cardiac injury, wound healing |
| Source | Thymus (PTMA cleavage) | Thymus and other tissues |
| Overlap | Minimal — distinct mechanisms |

---

## 10. Research Gaps & Future Directions

1. **Sepsis:** The TESTS Phase 3 trial (2025) was the largest and most rigorous — and found no benefit. Future work should focus on identifying **subpopulations** (e.g., those with low mHLA-DR) who may benefit from Tα1.

2. **Checkpoint Inhibitor Combinations:** Promising pre-clinical data showing Tα1 + anti-PD-1 antibodies have synergistic anti-tumor effects. Clinical trials combining Tα1 with modern immunotherapy are needed.

3. **Aging/Immunosenescence:** Given declining endogenous Tα1 with age, supplementation in elderly populations for general immune restoration remains underexplored.

4. **Autoimmune Disease:** Preliminary data suggest Tα1 may restore immune tolerance. Larger trials needed.

5. **Biomarker-Guided Therapy:** Using mHLA-DR, CD4/CD8 ratios, or other immune markers to identify patients most likely to benefit.

6. **Long-Acting Formulations:** The short half-life (<3h) necessitates frequent dosing. Tα1-Fc fusion proteins with prolonged half-lives have shown efficacy in pre-clinical melanoma/breast cancer models (Wang F, et al. *Sci Rep* 2018;8:12351).

---

## 11. Complete Reference List

1. Goldstein AL, et al. (1977). Thymosin α1: isolation and sequence analysis. *PNAS* 74(2):725–729.
2. Low TLK, et al. (1979). Thymosin α1 biological activities. *J Biol Chem* 254:981–986.
3. Dominari A, et al. (2020). Thymosin alpha 1: A comprehensive review of the literature. *World J Virol* 9(5):67–78. PMID: 33363000. PMC7747025.
4. Romani L, et al. (2007). Thymosin α1 activates TLR9/MyD88/IRF7 signaling. *Int Immunol* 19(11):1261–1270.
5. Tuthill C, et al. (2010). Thymosin α1: past clinical experience and future promise. *Ann NY Acad Sci* 1194:179–189.
6. Garaci E, et al. (2019). A reappraisal of thymosin alpha1 in cancer therapy. *Front Oncol* 9:873. PMC6742685.
7. Rost KL, et al. (1999). Pharmacokinetics of thymosin α1 after subcutaneous injection. *Int J Clin Pharmacol Ther* 37(1):51–57. PMID: 10027483.
8. Wu J, et al. (2013). ETASS: efficacy of thymosin α1 for severe sepsis. *Critical Care* 17:R8. PMC4056079.
9. Chen J, et al. (2025). TESTS: efficacy and safety of thymosin α1 for sepsis. *BMJ* 388:e082583. PMID: 39814420.
10. Liu Y, et al. (2021). Efficacy evaluation of thymosin α1 in non-severe COVID-19. *Front Med* 8:664776. PMC8102900.
11. Gravenstein S, et al. (2007). Thymosin α1 as adjunct to influenza vaccination in elderly. *Vaccine* 25(52):8736–8742. PMID: 17600281.
12. Panatto D, et al. (2011). Thymosin α1 as co-adjuvant in influenza vaccines. *J Prev Med Hyg* 52(3):111–115. PMID: 22010537.
13. Liu F, et al. (2016). Efficacy of thymosin α1 as immunomodulatory treatment for sepsis: systematic review. *BMC Infect Dis* 16:488.
14. Wang F, et al. (2018). Thymosin alpha1-Fc fusion protein in melanoma and breast cancer. *Sci Rep* 8:12351.
15. Armutcu F, et al. Protective effect of thymosin α1 against oxidative damage. (Referenced in Dominari 2020 review.)
16. Naylor PH, et al. Multiple targets for thymosin α1 immune-enhancing activity. (Referenced in Dominari 2020 review.)
17. Chan HL, et al. (2001). Thymosin α1 in chronic hepatitis B. *Hepatology* 33(3):1536–1542.
18. Chien RN, et al. (1998). Thymosin α1 in chronic hepatitis B. *Hepatology* 27:1383–1387.
19. Zhang Y, et al. (2023). Thymosin α1 and its role in viral infectious diseases. *Molecules* 28(8):3539.
20. Pei Y, et al. (2023). Use of alpha 1 thymosin as immunomodulator of response against SARS-CoV-2. *Immun Ageing* 20:33.
21. Li P, et al. (2025). Thymosin α1 alleviates inflammation in severe acute pancreatitis: systematic review and meta-analysis. *Front Immunol* 16:1571456.
22. Guo Y, et al. (2025). Efficacy of thymosin α1 for sepsis: systematic review and meta-analysis. *Front Cell Infect Microbiol* 15:1673959.
23. Antachopoulos C, et al. (2012). Thymosin α1 expression systems. (Referenced in Dominari 2020 review.)
24. Chen YL, et al. Thymosin α1 expression in yeast. (Referenced in Dominari 2020 review.)
25. Zadaxin (thymalfasin) prescribing information, SciClone Pharmaceuticals.
26. Li J, et al. (2023). Thymosin α-1 in cancer therapy: immunoregulation and potential applications. *Int Immunopharmacol* 116:109808.
27. Zhou Y, et al. (2025). Aging and thymosin alpha-1. *Int J Mol Sci* 26(23):11470.
28. Rasi G, et al. Combined treatment with thymosin-α1 and low-dose IFN-α after dacarbazine in advanced melanoma. *Melanoma Res*.

---

*Research compiled: 2026-02-01*
*Sources: PubMed, PMC, BMJ, Frontiers, RxList, MDPI, ScienceDirect, DrugBank, FDA submissions*
